CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 7, 2006--Researchers at Molecular Insight Pharmaceuticals announced today the presentation of preclinical data on Azedra(TM) (Ultratrace(TM) iobenguane I 131, or Ultratrace MIBG), the company’s lead oncology product candidate for the treatment of neuroendocrine tumors. The studies, presented at the 53rd Annual Meeting of the Society of Nuclear Medicine in San Diego, CA, were conducted in support of Azedra’s initial clinical trials in adult patients with neuroendocrine tumors. Azedra is a designated Orphan Drug under development for the treatment of neuroendocrine tumors such as carcinoid, neuroblastoma and pheochromocytoma.
